Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Travel fund to Swiss Nordic Bio 2019

Reference number
Funding from Vinnova SEK 6 815
Project duration February 2019 - February 2019
Status Completed

Purpose and goal

Participation completed including seminars, panel sessions and presence at multiple pitch presentations by various biotech companies in the early stage (potential Red Glead clients) as well as 6 scheduled1-to-1 meetings. The most important goal of effectively reaching more Life Science actors in Switzerland and the Nordics within the drug discovery space was fulfilled.

Expected effects and result

The most important effects were deepened relations with Novartis plus a couple of identified opportunities for research collaborations with other biotech companies. On a longer perspective, 1-2 new clients may be the result partly due to this meeting. Relevant intelligence updates on the Swiss and Nordic Life Science scene were effectively obtained.

Planned approach and implementation

CEO Johan Evenäs represented Red Glead Discovery during the meeting. Several new business contacts were made as well as maintained and deepened relations with previous contacts. Follow-up activities planned with Business Sweden.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 15 February 2019

Reference number 2018-05395

Page statistics